In contrast to the anti-BCMA IgG1 control that activated only CD16A+ NK cells, CTX-4419 induced potent killing of MM cells and IFN-γ production by KHGY-1, a CD16A- NKp30+ cell line, showing that CTX-4419 can redirect NK cell subsets with low expression of CD16A to kill MM cells. The gene discussed is NCR3; the disease is Miyoshi myopathy.